The mutual exclusivity of BRAF and KRAS mutations (Table 3) in our ovarian carcinoma is consistent with previous findings in ovarian carcinoma, melanoma, and colorectal carcinoma [43-45]. This evidence concerns the gene BRAF and colorectal carcinoma.